Antiepileptic drugs: newer targets and new drugs

2016-05-31T03-23-57Z
Source: International Journal of Basic & Clinical Pharmacology
Vihang S. Chawan, Abhishek M. Phatak, Kalpesh V. Gawand, Sagar V. Badwane, Sagar S. Panchal.
Epilepsy is a common neurological disorder affecting 0.5-1% of the population in India. Majority of patients respond to currently available antiepileptic drugs (AEDs), but a small percentage of patients have shown poor and inadequate response to AEDs in addition to various side effects and drug interactions while on therapy. Thus there is a need to develop more effective AEDs in drug resistant epilepsy which have a better safety profile with minimal adverse effects. The United States food and drug administration (USFDA) has approved eslicarbazepine acetate, ezogabine, perampanel and brivaracetam which have shown a promising future as better AEDs and drugs like ganaxolone, intranasal diazepam, ICA- 105665, valnoctamide, VX-765, naluzotan are in the pipeline.


from Scope via xlomafota13 on Inoreader http://ift.tt/1Z9ZVGX
via IFTTT